Physician profile
Pushkar Argekar
NPI 1063629657
$740.49
in general payments reported to CMS, 2019-2025
13 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.60 · 2021: $110 · 2022: $206 · 2023: $84.67 · 2024: $100 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.40 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $348.84 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $64.39 | 2024-2025 | |
| Amgen INC. | $43.76 | 2020-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $37.62 | 2024-2025 | |
| Akebia Therapeutics INC | $36.54 | 2020 | |
| Travere Therapeutics, INC. | $32.78 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $32.37 | 2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $29.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.52 | 2023 | Ultomiris |
| Ardelyx, INC. | $27.26 | 2024 | Ibsrela |
| Calliditas Therapeutics US INC. | $24.72 | 2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $19.86 | 2025 | Rayaldee |
| Horizon Therapeutics Plc | $12.91 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushkar Argekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.